2 reports of this reaction
2.2% of all ANTACID TABLETS reports
#8 most reported adverse reaction
PRODUCT SUBSTITUTION ISSUE is the #8 most commonly reported adverse reaction for ANTACID TABLETS, manufactured by Rising Pharma Holdings, Inc.. There are 2 FDA adverse event reports linking ANTACID TABLETS to PRODUCT SUBSTITUTION ISSUE. This represents approximately 2.2% of all 92 adverse event reports for this drug.
Patients taking ANTACID TABLETS who experience product substitution issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT SUBSTITUTION ISSUE is a less commonly reported adverse event for ANTACID TABLETS, but still significant enough to appear in the safety profile.
In addition to product substitution issue, the following adverse reactions have been reported for ANTACID TABLETS:
The following drugs have also been linked to product substitution issue in FDA adverse event reports:
PRODUCT SUBSTITUTION ISSUE has been reported as an adverse event in 2 FDA reports for ANTACID TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT SUBSTITUTION ISSUE accounts for approximately 2.2% of all adverse event reports for ANTACID TABLETS, making it a notable side effect.
If you experience product substitution issue while taking ANTACID TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.